Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum

被引：3
|
作者：
Idowu, Oladipo S. [1 ]
Craigen, Jenny L. [2 ]
Veal, Gareth J. [1 ]
Jamieson, David [1 ]
机构：
[1] Newcastle Univ, Newcastle Univ Ctr Canc, Newcastle Upon Tyne NE2 4HH, England
[2] Canc Res UK Ctr Drug Dev, London E20 1JQ, England
来源：
BIOANALYSIS | 2022年 / 14卷 / 18期
关键词：
assay validation; cancer; ELISA; HER3; pharmacokinetics; RECEPTOR HETERODIMERIZATION; ERBB3; EXPRESSION; GROWTH; CANCER; HER3;
D O I：
10.4155/bio-2022-0141
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Background: HMBD-001 is an IgG1 humanized monoclonal antibody specifically targeting HER3, a receptor highly expressed on cancer cells in certain tumors. A bioanalytical method was required to quantify HMBD-001 in human serum, with high selectivity and without interference from HER3. Methods and results: A bridging ELISA using an anti-idiotypic monoclonal capture and detection was developed and validated for quantitative measurement of HMBD-001 in human serum. The assay is sensitive, with a lower limit of quantification of 250 ng/ml, has a broad dynamic range of 250-7000 ng/ml HMBD-001, and exhibits excellent precision and overall accuracy. Conclusion: We have developed and validated a sensitive and selective method for measuring HMBD-001 in human serum. This assay is now being used in a clinical trial setting.
引用
收藏
页码：1241 / 1249
页数：9
相关论文
共 13 条
  • [1] Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse
    Meng, Qinghe
    Hao, Yimeng
    Yang, Mo
    Du, Yejie
    Wang, Shuling
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2024, 245
  • [2] First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
    Meulendijks, Didier
    Jacob, Wolfgang
    Martinez-Garcia, Maria
    Taus, Alvaro
    Lolkema, Martijn P.
    Voest, Emile E.
    Langenberg, Marlies H. G.
    Fleitas Kanonnikoff, Tania
    Cervantes, Andres
    De Jonge, Maja J.
    Sleijfer, Stefan
    Soerensen, Morten Mau
    Thomas, Marlene
    Ceppi, Maurizio
    Meneses-Lorente, Georgina
    James, Ian
    Adessi, Celine
    Michielin, Francesca
    Abiraj, Keelara
    Bossenmaier, Birgit
    Schellens, Jan H. M.
    Weisser, Martin
    Lassen, Ulrik N.
    CLINICAL CANCER RESEARCH, 2016, 22 (04) : 877 - 885
  • [3] A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors
    Gan, Hui K.
    Millward, Michael
    Jalving, Mathilde
    Garrido-Laguna, Ignacio
    Lickliter, Jason D.
    Schellens, Jan H. M.
    Lolkema, Martijn P.
    Van Herpen, Carla L. M.
    Hug, Bruce
    Tang, Lihua
    O'Connor-Semmes, Robin
    Gagnon, Robert
    Ellis, Catherine
    Ganji, Gopinath
    Matheny, Christopher
    Drilon, Alexander
    ONCOLOGIST, 2021, 26 (10) : E1844 - E1853
  • [4] Phase I Study of U3-1287, a Fully Human Anti-HER3 Monoclonal Antibody, in Patients with Advanced Solid Tumors
    LoRusso, Patricia
    Jaenne, Pasi A.
    Oliveira, Moacyr
    Rizvi, Naiyer
    Malburg, Lisa
    Keedy, Vicki
    Yee, Lorrin
    Copigneaux, Catherine
    Hettmann, Thore
    Wu, Chi-Yuan
    Ang, Agnes
    Halim, Abdel-Baset
    Beckman, Robert A.
    Beaupre, Darrin
    Berlin, Jordan
    CLINICAL CANCER RESEARCH, 2013, 19 (11) : 3078 - 3087
  • [5] Development and validation of an LC-MS/MS method for the quantification of fascin proteins in human serum
    Li, Ke
    Zhang, Zhiling
    Wang, Kai
    Huang, Xin-Yun
    Lin, Zhongping
    BIOANALYSIS, 2022, 14 (16) : 1095 - 1109
  • [6] The development and validation of a microneutralization assay for the detection and quantification of anti-yellow fever virus antibodies in human serum
    Fries, Katherine
    Luo, Ping
    Baldwin, Rebekah
    Goldberg, Raechel
    Ordonez, Ivan
    Zheng, Lingyi
    Huleatt, James
    Devlin, Louis
    MICROBIOLOGY SPECTRUM, 2025,
  • [7] Phase 1 study of new formulation of patritumab (U3-1287) Process 2, a fully human anti-HER3 monoclonal antibody in combination with erlotinib in Japanese patients with advanced non-small cell lung cancer
    Shimizu, Toshio
    Yonesaka, Kimio
    Hayashi, Hidetoshi
    Iwasa, Tsutomu
    Haratani, Koji
    Yamada, Hironori
    Ohwada, Shoichi
    Kamiyama, Emi
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (03) : 489 - 495
  • [8] Development, validation and application of ELISAs for pharmacokinetic and HACA assessment of a chimeric anti-CD40 monoclonal antibody in human serum
    Chowdhury, F.
    Tutt, A. L.
    Chan, C.
    Glennie, M.
    Johnson, P. W.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2010, 363 (01) : 1 - 8
  • [9] Development and validation of an HPLC-MS/MS method for the quantification of the anti-leishmanial drug miltefosine in human skin tissue
    Roseboom, Ignace C.
    Thijssen, Bas
    Rosing, Hilde
    Alves, Fabiana
    Mondal, Dinesh
    Teunissen, Marcel B. M.
    Beijnen, Jos H.
    Dorlo, Thomas P. C.
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2022, 207
  • [10] Development and validation of an enzyme-linked immunosorbent assay for the quantification of a recombinant humanized anti-IL-4Rα monoclonal antibody CM310 in serum and its application to pharmacokinetic study in Sprague-Dawley Rats
    Hao, Yimeng
    Zhang, Libo
    Meng, Qinghe
    Jia, Qian
    Ma, Jing
    Zhang, Xuemei
    ANALYTICAL BIOCHEMISTRY, 2024, 694
12